Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2016 - 2025)

Historic Accumulated Depreciation for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $27.4 million.

  • Rocket Pharmaceuticals' Accumulated Depreciation rose 4124.34% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 4124.34%. This contributed to the annual value of $21.3 million for FY2024, which is 5146.09% up from last year.
  • Rocket Pharmaceuticals' Accumulated Depreciation amounted to $27.4 million in Q3 2025, which was up 4124.34% from $25.7 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Accumulated Depreciation's 5-year high stood at $27.4 million during Q3 2025, with a 5-year trough of $2.7 million in Q1 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Accumulated Depreciation had a median value of $11.4 million in 2023 and averaged $12.9 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Accumulated Depreciation skyrocketed by 20035.06% in 2021 and then soared by 4124.34% in 2025.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Accumulated Depreciation stood at $5.2 million in 2021, then surged by 74.1% to $9.1 million in 2022, then surged by 54.32% to $14.0 million in 2023, then skyrocketed by 51.46% to $21.3 million in 2024, then increased by 29.13% to $27.4 million in 2025.
  • Its Accumulated Depreciation stands at $27.4 million for Q3 2025, versus $25.7 million for Q2 2025 and $23.7 million for Q1 2025.